Loading…

Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity

In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe ( = 17) and severe COVID-19 ( = 11). The serum/plasma samples were studied for the presence of IgG, IgM and Ig...

Full description

Saved in:
Bibliographic Details
Published in:Antibodies (Basel) 2023-02, Vol.12 (1), p.19
Main Authors: Desheva, Yulia, Lerner, Anna, Shvedova, Tamara, Kopteva, Olga, Kudar, Polina, Koroleva, Irina, Leontieva, Galina, Suvorov, Alexander
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903
cites cdi_FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903
container_end_page
container_issue 1
container_start_page 19
container_title Antibodies (Basel)
container_volume 12
creator Desheva, Yulia
Lerner, Anna
Shvedova, Tamara
Kopteva, Olga
Kudar, Polina
Koroleva, Irina
Leontieva, Galina
Suvorov, Alexander
description In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe ( = 17) and severe COVID-19 ( = 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r = 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r = 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.
doi_str_mv 10.3390/antib12010019
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_190d1207d7ee4942b93721ac904955ed</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743462055</galeid><doaj_id>oai_doaj_org_article_190d1207d7ee4942b93721ac904955ed</doaj_id><sourcerecordid>A743462055</sourcerecordid><originalsourceid>FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903</originalsourceid><addsrcrecordid>eNptks2PEyEUwCdG427WPXo1JF68zMrHAMPJNPWrycZtttorofCmZTOFlWHW9O4fLrXrujXCAQI_fvAer6peEnzBmMJvTch-RSgmGBP1pDqlWLK6aUT79NH8pDofhhtcmsRUUPW8OmFCSc6EOK1-zn0fM1rk0e3QNQxjnwcUA5rszdF5GFCOKG8ALWpkgkNf6nmKGXwoWIcWk-tFPY3LmiIf0Nz4BA4tIBnUpbhF06vl7H1NVNnJHkJR__B5g5Ym7XxYF_AOks-7F9WzzvQDnN-PZ9W3jx--Tj_Xl1efZtPJZW15o3LNGmGNcJZLKYkTrcDcGIyBCNcJahvMVi1dccqgbaRkYLi1SrSKGCkMVpidVbOD10Vzo2-T35aH6Gi8_r0Q01qblL3tQROFXUmsdBKgUQ1dKSYpMVbhRnEOrrjeHVy342oLzpbokumPpMc7wW_0Ot7p8lcNL_9QDG_uDSl-H2HIeusHC31vAsRx0FQqyrHgrSro63_QmzimUHK1pwgXVEj6l1qbEoEPXSwX271UT2RTskcx54W6-A9VuoOttzFA58v60YH6cMCmOAwJuocgCdb7MtRHZVj4V48z80D_KTr2Cwd80-8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2791562672</pqid></control><display><type>article</type><title>Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity</title><source>Access via ProQuest (Open Access)</source><source>PubMed Central</source><creator>Desheva, Yulia ; Lerner, Anna ; Shvedova, Tamara ; Kopteva, Olga ; Kudar, Polina ; Koroleva, Irina ; Leontieva, Galina ; Suvorov, Alexander</creator><creatorcontrib>Desheva, Yulia ; Lerner, Anna ; Shvedova, Tamara ; Kopteva, Olga ; Kudar, Polina ; Koroleva, Irina ; Leontieva, Galina ; Suvorov, Alexander</creatorcontrib><description>In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe ( = 17) and severe COVID-19 ( = 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r = 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r = 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.</description><identifier>ISSN: 2073-4468</identifier><identifier>EISSN: 2073-4468</identifier><identifier>DOI: 10.3390/antib12010019</identifier><identifier>PMID: 36975366</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adaptive immunity ; Amino acid metabolism ; Antibodies ; Blood pressure ; blood tests ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Enzymes ; Ethics ; Ethylenediaminetetraacetic acid ; Health aspects ; Hospitalization ; Immunoglobulin A ; Immunoglobulin G ; Immunoglobulin M ; Infection ; Infections ; Laboratories ; Lymphocytes ; Measurement ; Medical research ; Neutrophils ; Oxygen saturation ; Pathogenesis ; Personal information ; Polymerase chain reaction ; Protein folding ; Proteins ; Respiration ; Respiratory diseases ; serum antibodies ; Severe acute respiratory syndrome coronavirus 2 ; severity ; Software ; Testing ; Vaccines ; Viral antibodies ; Viral infections</subject><ispartof>Antibodies (Basel), 2023-02, Vol.12 (1), p.19</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903</citedby><cites>FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903</cites><orcidid>0000-0002-9876-6594 ; 0000-0001-9794-3520 ; 0000-0002-6649-8150 ; 0000-0002-3342-5828</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2791562672/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2791562672?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36975366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Desheva, Yulia</creatorcontrib><creatorcontrib>Lerner, Anna</creatorcontrib><creatorcontrib>Shvedova, Tamara</creatorcontrib><creatorcontrib>Kopteva, Olga</creatorcontrib><creatorcontrib>Kudar, Polina</creatorcontrib><creatorcontrib>Koroleva, Irina</creatorcontrib><creatorcontrib>Leontieva, Galina</creatorcontrib><creatorcontrib>Suvorov, Alexander</creatorcontrib><title>Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity</title><title>Antibodies (Basel)</title><addtitle>Antibodies (Basel)</addtitle><description>In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe ( = 17) and severe COVID-19 ( = 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r = 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r = 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.</description><subject>Adaptive immunity</subject><subject>Amino acid metabolism</subject><subject>Antibodies</subject><subject>Blood pressure</subject><subject>blood tests</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Enzymes</subject><subject>Ethics</subject><subject>Ethylenediaminetetraacetic acid</subject><subject>Health aspects</subject><subject>Hospitalization</subject><subject>Immunoglobulin A</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin M</subject><subject>Infection</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Measurement</subject><subject>Medical research</subject><subject>Neutrophils</subject><subject>Oxygen saturation</subject><subject>Pathogenesis</subject><subject>Personal information</subject><subject>Polymerase chain reaction</subject><subject>Protein folding</subject><subject>Proteins</subject><subject>Respiration</subject><subject>Respiratory diseases</subject><subject>serum antibodies</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>severity</subject><subject>Software</subject><subject>Testing</subject><subject>Vaccines</subject><subject>Viral antibodies</subject><subject>Viral infections</subject><issn>2073-4468</issn><issn>2073-4468</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks2PEyEUwCdG427WPXo1JF68zMrHAMPJNPWrycZtttorofCmZTOFlWHW9O4fLrXrujXCAQI_fvAer6peEnzBmMJvTch-RSgmGBP1pDqlWLK6aUT79NH8pDofhhtcmsRUUPW8OmFCSc6EOK1-zn0fM1rk0e3QNQxjnwcUA5rszdF5GFCOKG8ALWpkgkNf6nmKGXwoWIcWk-tFPY3LmiIf0Nz4BA4tIBnUpbhF06vl7H1NVNnJHkJR__B5g5Ym7XxYF_AOks-7F9WzzvQDnN-PZ9W3jx--Tj_Xl1efZtPJZW15o3LNGmGNcJZLKYkTrcDcGIyBCNcJahvMVi1dccqgbaRkYLi1SrSKGCkMVpidVbOD10Vzo2-T35aH6Gi8_r0Q01qblL3tQROFXUmsdBKgUQ1dKSYpMVbhRnEOrrjeHVy342oLzpbokumPpMc7wW_0Ot7p8lcNL_9QDG_uDSl-H2HIeusHC31vAsRx0FQqyrHgrSro63_QmzimUHK1pwgXVEj6l1qbEoEPXSwX271UT2RTskcx54W6-A9VuoOttzFA58v60YH6cMCmOAwJuocgCdb7MtRHZVj4V48z80D_KTr2Cwd80-8</recordid><startdate>20230227</startdate><enddate>20230227</enddate><creator>Desheva, Yulia</creator><creator>Lerner, Anna</creator><creator>Shvedova, Tamara</creator><creator>Kopteva, Olga</creator><creator>Kudar, Polina</creator><creator>Koroleva, Irina</creator><creator>Leontieva, Galina</creator><creator>Suvorov, Alexander</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-9876-6594</orcidid><orcidid>https://orcid.org/0000-0001-9794-3520</orcidid><orcidid>https://orcid.org/0000-0002-6649-8150</orcidid><orcidid>https://orcid.org/0000-0002-3342-5828</orcidid></search><sort><creationdate>20230227</creationdate><title>Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity</title><author>Desheva, Yulia ; Lerner, Anna ; Shvedova, Tamara ; Kopteva, Olga ; Kudar, Polina ; Koroleva, Irina ; Leontieva, Galina ; Suvorov, Alexander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adaptive immunity</topic><topic>Amino acid metabolism</topic><topic>Antibodies</topic><topic>Blood pressure</topic><topic>blood tests</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Enzymes</topic><topic>Ethics</topic><topic>Ethylenediaminetetraacetic acid</topic><topic>Health aspects</topic><topic>Hospitalization</topic><topic>Immunoglobulin A</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin M</topic><topic>Infection</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Measurement</topic><topic>Medical research</topic><topic>Neutrophils</topic><topic>Oxygen saturation</topic><topic>Pathogenesis</topic><topic>Personal information</topic><topic>Polymerase chain reaction</topic><topic>Protein folding</topic><topic>Proteins</topic><topic>Respiration</topic><topic>Respiratory diseases</topic><topic>serum antibodies</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>severity</topic><topic>Software</topic><topic>Testing</topic><topic>Vaccines</topic><topic>Viral antibodies</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Desheva, Yulia</creatorcontrib><creatorcontrib>Lerner, Anna</creatorcontrib><creatorcontrib>Shvedova, Tamara</creatorcontrib><creatorcontrib>Kopteva, Olga</creatorcontrib><creatorcontrib>Kudar, Polina</creatorcontrib><creatorcontrib>Koroleva, Irina</creatorcontrib><creatorcontrib>Leontieva, Galina</creatorcontrib><creatorcontrib>Suvorov, Alexander</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Antibodies (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Desheva, Yulia</au><au>Lerner, Anna</au><au>Shvedova, Tamara</au><au>Kopteva, Olga</au><au>Kudar, Polina</au><au>Koroleva, Irina</au><au>Leontieva, Galina</au><au>Suvorov, Alexander</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity</atitle><jtitle>Antibodies (Basel)</jtitle><addtitle>Antibodies (Basel)</addtitle><date>2023-02-27</date><risdate>2023</risdate><volume>12</volume><issue>1</issue><spage>19</spage><pages>19-</pages><issn>2073-4468</issn><eissn>2073-4468</eissn><abstract>In this retrospective cohort study, we investigated the formation of individual classes of antibodies to SARS-CoV-2 in archived serial sera from hospitalized patients with the medium-severe ( = 17) and severe COVID-19 ( = 11). The serum/plasma samples were studied for the presence of IgG, IgM and IgA antibodies to the recombinant S- and N-proteins of SARS-CoV-2. By the 7th day of hospitalization, an IgG increase was observed in patients both with a positive PCR test and without PCR confirmation of SARS-CoV-2 infection. Significant increases in the anti-spike IgG levels were noted only in moderate COVID-19. The four-fold increase of IgM to N-protein was obtained more often in the groups with mild and moderate infections. The IgA levels decreased during the infection to both the S- and N-proteins, and the most pronounced decrease was in the severe COVID-19 patients. The serum IgG to S-protein one week after hospitalization demonstrated a high-power relationship (r = 0.75) with the level of RBD antibodies. There was a medium strength relationship between the levels of CRP and IgG (r = 0.43). Thus, in patients with acute COVID-19, an increase in antibodies can develop as early as 1 week of hospital stay. The SARS-CoV-2 antibody conversions may confirm SARS-CoV-2 infection in PCR-negative patients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36975366</pmid><doi>10.3390/antib12010019</doi><orcidid>https://orcid.org/0000-0002-9876-6594</orcidid><orcidid>https://orcid.org/0000-0001-9794-3520</orcidid><orcidid>https://orcid.org/0000-0002-6649-8150</orcidid><orcidid>https://orcid.org/0000-0002-3342-5828</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2073-4468
ispartof Antibodies (Basel), 2023-02, Vol.12 (1), p.19
issn 2073-4468
2073-4468
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_190d1207d7ee4942b93721ac904955ed
source Access via ProQuest (Open Access); PubMed Central
subjects Adaptive immunity
Amino acid metabolism
Antibodies
Blood pressure
blood tests
Coronaviruses
COVID-19
COVID-19 vaccines
Enzymes
Ethics
Ethylenediaminetetraacetic acid
Health aspects
Hospitalization
Immunoglobulin A
Immunoglobulin G
Immunoglobulin M
Infection
Infections
Laboratories
Lymphocytes
Measurement
Medical research
Neutrophils
Oxygen saturation
Pathogenesis
Personal information
Polymerase chain reaction
Protein folding
Proteins
Respiration
Respiratory diseases
serum antibodies
Severe acute respiratory syndrome coronavirus 2
severity
Software
Testing
Vaccines
Viral antibodies
Viral infections
title Pilot Study Results on Antibodies to the S- and N-Proteins of SARS-CoV-2 in Paired Sera from COVID-19 Patients with Varying Severity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T13%3A09%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pilot%20Study%20Results%20on%20Antibodies%20to%20the%20S-%20and%20N-Proteins%20of%20SARS-CoV-2%20in%20Paired%20Sera%20from%20COVID-19%20Patients%20with%20Varying%20Severity&rft.jtitle=Antibodies%20(Basel)&rft.au=Desheva,%20Yulia&rft.date=2023-02-27&rft.volume=12&rft.issue=1&rft.spage=19&rft.pages=19-&rft.issn=2073-4468&rft.eissn=2073-4468&rft_id=info:doi/10.3390/antib12010019&rft_dat=%3Cgale_doaj_%3EA743462055%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c549t-346ca6dc57771d68605aa00e16df62c403b82b523e84773ea5cc96891a76a0903%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2791562672&rft_id=info:pmid/36975366&rft_galeid=A743462055&rfr_iscdi=true